$BAX

The FDA issued warning letters to Baxter International and Olympus Medical Systems for GMP and QSR violations. Baxter's Round Lake facility was cited for contamination risks, inadequate procedures, and recurring sterility issues. Olympus faced violations at six facilities, including failure to address known hazards and inadequate risk management. Both companies were advised to take corrective actions.

Baxter International (BAX) received an FDA warning letter for its Illinois facility, citing cross-contamination, inadequate sterilization, and inspection issues. Wolfe Research maintained a Peerperform rating, noting the stock trades below its fair value. Seven analysts revised earnings downward ahead of the company's upcoming earnings report. Despite the regulatory challenges, Baxter reported strong Q2 2026 results, exceeding earnings and revenue expectations, and raised its full-year outlook.

CooperCompanies (COO) underperformed peers with weak results and guidance, stock down 14%. Baxter (BAX) beat estimates with 5.3% revenue growth, stock flat. Boston Scientific (BSX) missed guidance, stock down 6.2%. Abbott Labs (ABT) grew 13%, stock up 15.4%. Neogen (NEOG) beat estimates, stock down 2%. Market update discusses shifting investor concerns.

Citigroup maintained a Neutral rating for Baxter International (BAX) but lowered its price target to $27.00 from $28.00. Baxter's GF Value™ is $31.70, suggesting a 23.6% undervaluation, but the company is currently unprofitable with a P/S ratio of 8.47. Baxter's GF Score™ is 70/100, indicating moderate financial health and performance.

Baxter (BAX) reported Q2 revenue of $2.96B, up 5.3% YoY, beating estimates. LeMaitre (LMAT) reported $70.38M, up 9.6% YoY, missing estimates. STERIS (STE) reported $1.49B, up 7.3% YoY, in line with estimates. Lantheus (LNTH) reported $388.2M, up 2.7% YoY, beating estimates. Stocks are down since reporting.

Baxter International (BAX) has underperformed rival Becton, Dickinson (BDX) with a 22.8% gain over 52 weeks but lagged on a YTD basis with an 18.3% increase. Analysts give BAX a consensus 'Hold' rating, with a mean price target of $27, implying an 18.4% upside from current levels.

Otsuka ICU Medical recalled a lot of 0.9% Sodium Chloride Injection due to a mix-up with highly concentrated Potassium Chloride. Baxter International recalled two lots of the same product over potential fiberglass contamination. Both recalls were issued by the FDA.

Baxter and B. Braun recalled IV saline bags due to fiberglass and rust particles. Baxter recalled sodium chloride, sodium citrate, and dextrose lots, while B. Braun recalled sodium chloride. No injuries reported, but particles pose serious risks if they enter the bloodstream. Baxter's North Cove plant supplies 60% of U.S. IV fluids, raising concerns about potential shortages. The FDA has not yet classified these recalls.

Baxter International Inc. (BAX) raised its 2026 outlook despite margin pressure, citing strong Q2 growth. The company continues to work with regulators and faces potential customer uncertainty. Becton, Dickinson and Company (BDX) and ICU Medical, Inc. (ICUI) also compete in the infusion technology market. BAX has a Zacks Rank #3 (Hold), with a Value Score of B, Growth Score of B, and VGM Score of B, but a Momentum Score of C.

Baxter International recalled two lots of 0.9% Sodium Chloride injection and one lot of Anticoagulant Sodium Citrate Solution due to potential fiberglass particles, according to the FDA. The recalls were issued on Aug. 25 and 26, with distribution dates in July. Baxter stated no adverse events have been reported as of Sept. 3, 2026, and they are working with the FDA.